Article
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2012
Branford Susan, Kim Dong-Wook, Soverini Simona, Haque Ariful, Shou Yaping, Woodman Richard C, Kantarjian Hagop M, Martinelli Giovanni, Radich Jerald P, Saglio Giuseppe, Hochhaus Andreas, Hughes Timothy P, Müller Martin C
Abstract excerpt
PURPOSE: The association between initial molecular response and longer-term outcomes with nilotinib was examined. PATIENTS AND METHODS: Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbasel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.